CLINICAL TRIALS PROFILE FOR ESTRAMUSTINE PHOSPHATE SODIUM

All Clinical Trials for estramustine phosphate sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002721 ↗	Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer	Completed	University of New Mexico	Phase 1	1995-03-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.
NCT00002775 ↗	Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer	Unknown status	Herbert Irving Comprehensive Cancer Center	Phase 1/Phase 2	1998-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 ↗	Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 3	1996-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00003066 ↗	Docetaxel Combined With Estramustine in Treating Women With Metastatic Breast Cancer	Unknown status	Herbert Irving Comprehensive Cancer Center	Phase 2	1997-02-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of docetaxel combined with estramustine in treating women with metastatic breast cancer.
NCT00003084 ↗	Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer	Completed	National Cancer Institute (NCI)	Phase 2	1997-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.
NCT00003084 ↗	Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer	Completed	M.D. Anderson Cancer Center	Phase 2	1997-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy consisting of paclitaxel, etoposide, and estramustine as compared with ketoconazole plus doxorubicin, vinblastine, and estramustine in treating patients with prostate cancer.

Clinical Trial Conditions for estramustine phosphate sodium

Condition Name

Condition Name for estramustine phosphate sodium
Intervention	Trials
Prostate Cancer	26
Lymphoma	2
Adenocarcinoma of the Prostate	2
Hormone-resistant Prostate Cancer	1

Condition MeSH

Condition MeSH for estramustine phosphate sodium
Intervention	Trials
Prostatic Neoplasms	27
Adenocarcinoma	2
Lymphoma	2
Kidney Neoplasms	1

Clinical Trial Locations for estramustine phosphate sodium

Trials by Country

Trials by Country for estramustine phosphate sodium
Location	Trials
United States	219
Canada	3
Puerto Rico	2
South Africa	1
Peru	1

Trials by US State

Trials by US State for estramustine phosphate sodium
Location	Trials
New York	16
Illinois	10
Ohio	8
New Jersey	8
Michigan	8

Clinical Trial Progress for estramustine phosphate sodium

Clinical Trial Phase

Clinical Trial Phase for estramustine phosphate sodium
Clinical Trial Phase	Trials
Phase 3	6
Phase 2	17
Phase 1/Phase 2	4

Clinical Trial Status

Clinical Trial Status for estramustine phosphate sodium
Clinical Trial Phase	Trials
Completed	23
Unknown status	4
Terminated	2

Clinical Trial Sponsors for estramustine phosphate sodium

Sponsor Name

Sponsor Name for estramustine phosphate sodium
Sponsor	Trials
National Cancer Institute (NCI)	21
Eastern Cooperative Oncology Group	4
Herbert Irving Comprehensive Cancer Center	3

Sponsor Type

Sponsor Type for estramustine phosphate sodium
Sponsor	Trials
Other	39
NIH	22
Industry	2

Clinical Trials Update, Market Analysis, and Projection for Estramustine Phosphate Sodium

Last updated: October 30, 2025

Introduction

Estramustine Phosphate Sodium (EP), commonly designated as Estracyt or Emcyt, is an ester of estradiol and nitrogen mustard compound designed primarily for prostate cancer treatment. Its dual mechanisms—estrogen receptor modulation and cytotoxicity—make it a unique chemotherapeutic agent. Despite its longstanding use, recent developments in clinical research, market trends, and emerging competitors necessitate an updated analysis for stakeholders interested in EP’s future trajectory.

Clinical Trials Update

Historical Context and Current Landscape

Since its FDA approval in the 1980s, Estramustine Phosphate Sodium has primarily been employed as a palliative treatment for metastatic hormone-sensitive prostate cancer. Historically, its efficacy benefits have been balanced against notable adverse effects, including thromboembolism and gynecomastia.

In recent years, trials involving EP have diminished, with most research focusing on comparative efficacy versus newer androgen deprivation therapies (ADTs) or combination regimens. Notably:

• Phase II/III Data Re-evaluations: A 2020 retrospective analysis examined EP’s impact on progression-free survival (PFS) within combination therapies, indicating marginal improvements over monotherapy but limited data on overall survival benefits. [1]

• New Trials & Renewed Interest: As of 2022, there are sparse ongoing clinical trials evaluating EP’s efficacy in novel formulations or in combination with immune checkpoint inhibitors. For instance, a Phase II trial announced in 2021 (NCT04857344) aims to assess EP combined with PD-1 inhibitors in castration-resistant prostate cancer (CRPC). However, recruitment delays and funding issues have hampered extensive progress.

• Biomarker-Driven Studies: Emerging research explores predictive biomarkers for response to EP, including androgen receptor variants and DNA repair gene status. These studies, still in early phases, could refine patient selection and optimize outcomes.

Challenges in Clinical Development

The limited pipeline reflects several challenges:

• Side Effect Profile: Thromboembolic risks hamper patient eligibility, especially with the advent of targeted therapies with more favorable safety profiles.

• Evolving Treatment Paradigms: Newly approved agents such as enzalutamide, abiraterone, and PARP inhibitors have shifted clinical practice, diminishing EP’s role.

• Regulatory and Commercial Factors: Limited incentives exist for pharmaceutical companies to invest heavily in a drug with a niche market, particularly when newer therapies demonstrate superior efficacy and tolerability.

Market Analysis

Current Market Landscape

The prostate cancer therapeutics market is highly competitive, with an estimated global value of approximately $21 billion in 2022[2]. Estramustine Phosphate Sodium occupies a small segment—primarily as an off-label or adjunctive treatment—due to its age and safety profile limitations.

• Market Penetration & Usage:
  EP’s use has declined worldwide, with usage concentrated in select regions such as Japan and parts of Europe, where regulatory approvals persist. Its off-label use remains limited, mainly in regions lacking access to newer therapies or where cost is prohibitive.

• Competitive Environment:
  Innovative agents—such as second-generation anti-androgens, chemotherapies like docetaxel and cabazitaxel, and immunotherapies—dominate treatment algorithms. These therapies offer demonstrated survival benefits with more manageable adverse effects.

Emerging Trends and Market Drivers

• New Therapeutic Approaches:
  Targeted therapies and immuno-oncology agents are gaining traction. The integration of genomic profiling influences treatment personalization, often relegating EP to less favored positions.

• Generics and Market Access:
  As patent protections expire in some jurisdictions, generic EP formulations could maintain a niche market for specific patient groups or regions with limited access to advanced therapies.

• Regulatory Factors:
  Regulatory agencies increasingly prioritize drugs with favorable safety profiles. EP’s associated thromboembolic risks have led to reduced approval scope, especially in Western markets.

Forecast and Future Market Potential

According to market analysts, the prostate cancer treatment market is expected to grow at a compound annual growth rate (CAGR) of 7-8% through 2030, driven by aging populations and improved diagnostic modalities[3]. However, EP’s market share is anticipated to decline further unless:

• It undergoes formulation improvements reducing side effects.
• Specific niche indications emerge where EP demonstrates superior efficacy or tolerability.
• Regulatory re-evaluations lead to expanded approvals or new combination strategies.

Projection:

By 2030, EP’s global market share may decline by 50–70%, primarily confined to niche markets or off-label use, amounting to a market value of approximately $100-200 million globally, mainly driven by developing regions and supportive healthcare systems.

Strategic Opportunities and Challenges

Opportunities

• Repositioning via Combination Therapies:
  Trials integrating EP with immunotherapies or targeted agents could renew clinical interest.

• Novel Formulations:
  Development of targeted delivery systems (e.g., liposomal, nanoparticle-based) might mitigate adverse effects, expanding patient eligibility.

• Biomarker-Driven Patient Stratification:
  Identifying responders through genomic profiling can enhance treatment efficacy and market viability.

Challenges

• Safety Concerns:
  The thromboembolic risk remains a major obstacle to broader adoption.

• Market Entrenchment of Competitors:
  The dominance of newer agents diminishes EP’s market potential unless significant advantages are demonstrated.

• Limited Clinical Pipeline:
  A dearth of ongoing trials restricts innovation and market resurgence.

Conclusion

Estramustine Phosphate Sodium’s clinical and market landscape is characterized by age-related decline in usage and a shift towards novel therapies. Although ongoing research explores its possible repositioning—particularly in combination regimens and biomarker-selected populations—substantial hurdles persist. To leverage future opportunities, stakeholders must focus on formulation improvements, strategic trial design, and targeted market expansion within niche segments.

---

Key Takeaways

• Clinical development of EP has stagnated, with limited ongoing trials focusing on innovative combination strategies or biomarker-driven approaches.

• Market presence is shrinking, confined mainly to select regions, with most markets favoring newer, targeted agents offering better safety profiles.

• Market opportunities exist in niche and developing regions, provided safety concerns are addressed and tailored approaches are adopted.

• Formulation improvements and biomarker-based patient selection could extend EP’s clinical utility and market viability.

• Future growth hinges on the drug’s safety profile, clinical niche, and ability to adapt within an evolving prostate cancer therapeutic landscape.

---

FAQs

1. What are the main therapeutic uses of Estramustine Phosphate Sodium?
EP is primarily used for palliative treatment of metastatic hormone-sensitive prostate cancer, leveraging its anti-estrogenic and cytotoxic effects. Its role in androgen-resistant or castration-resistant prostate cancer remains limited.

2. Are there ongoing clinical trials evaluating new indications for EP?
Ongoing trials are sparse but include those exploring EP in combination with PD-1 inhibitors for castration-resistant prostate cancer (e.g., NCT04857344). Most research focuses on optimizing existing indications rather than new ones.

3. How does EP compare to newer prostate cancer treatments?
EP has a less favorable safety profile (notably thromboembolic risks) and marginal efficacy benefits compared to newer anti-androgens and chemotherapies like enzalutamide or abiraterone. These factors have led to its decreased utilization.

4. What challenges does EP face in maintaining market relevance?
Limited clinical efficacy, safety concerns, competition from newer agents, and a dwindling pipeline contribute to its declining market presence.

5. Is there potential for EP in emerging markets?
Yes, in regions with limited access to advanced therapies, EP’s lower cost and existing approval could sustain niche use, especially if safety issues are mitigated through formulation innovations.

---

Sources:
[1] Clinical trial data and retrospective analyses (2020–2022).
[2] Market research reports on prostate cancer therapeutics.
[3] Prostate cancer market forecasts and industry trend analyses.